T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$2.31B |
| 2 |
Apple
AAPL
|
+$1.58B |
| 3 |
Sherwin-Williams
SHW
|
+$1.37B |
| 4 |
HubSpot
HUBS
|
+$1.32B |
| 5 |
Kenvue
KVUE
|
+$1.25B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.37B |
| 2 |
Lam Research
LRCX
|
+$1.54B |
| 3 |
Applied Materials
AMAT
|
+$1.33B |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$1.19B |
| 5 |
Halliburton
HAL
|
+$1.16B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.32% |
| 2 | Healthcare | 15.15% |
| 3 | Financials | 10.54% |
| 4 | Consumer Discretionary | 10.48% |
| 5 | Communication Services | 8.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1201
ArcBest
ARCB
$3.28B
| $7.2M | ﹤0.01% |
66,384
-10,458
| -14% | -$1.15M |
|
1202
Regal Rexnord
RRX
$11.4B
| $7.11M | ﹤0.01% |
42,857
+2,292
| +6% | +$354K |
|
1203
WPP
WPP
$5.82B
| $7.11M | ﹤0.01% |
+138,909
| New | +$6.61M |
|
1204
Fox Class B
FOX
$24.4B
| $7.05M | ﹤0.01% |
181,653
+4,232
| +2% | +$153K |
|
1205
Coca-Cola Femsa
KOF
$23.1B
| $7.04M | ﹤0.01% |
79,300
+15,300
| +24% | +$1.34M |
|
|
NARI
1206
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $7.03M | ﹤0.01% |
170,442
-133,591
| -44% | -$6.41M |
|
1207
Grupo Cibest SA
CIB
$22.6B
| $7.01M | ﹤0.01% |
223,452
+31,723
| +17% | +$1.04M |
|
1208
Timken Company
TKR
$9.03B
| $6.97M | ﹤0.01% |
82,671
+2,740
| +3% | +$225K |
|
1209
Hawkins
HWKN
$2.67B
| $6.93M | ﹤0.01% |
54,372
+771
| +1% | +$87.3K |
|
1210
PBF Energy
PBF
$8.81B
| $6.86M | ﹤0.01% |
221,536
-5,765
| -3% | -$209K |
|
|
ORKA
1211
Oruka Therapeutics
ORKA
$7.16B
| $6.86M | ﹤0.01% |
+279,648
| New | +$9.73M |
|
|
BERY
1212
DELISTED
Berry Global Group, Inc.
BERY
| $6.83M | ﹤0.01% |
109,379
+3,285
| +3% | +$195K |
|
|
SPR
1213
DELISTED
Spirit AeroSystems
SPR
| $6.78M | ﹤0.01% |
208,476
-8,009,122
| -97% | -$274M |
|
1214
RingCentral
RNG
$5.25B
| $6.77M | ﹤0.01% |
214,007
+157,286
| +277% | +$4.97M |
|
1215
Kemper
KMPR
$1.56B
| $6.76M | ﹤0.01% |
110,353
+5,293
| +5% | +$325K |
|
1216
Brookfield
BN
$111B
| $6.74M | ﹤0.01% |
+190,257
| New | +$6M |
|
1217
Corbus Pharmaceuticals
CRBP
$189M
| $6.72M | ﹤0.01% |
325,668
+23,482
| +8% | +$1.2M |
|
1218
ARS Pharmaceuticals
SPRY
$606M
| $6.71M | ﹤0.01% |
462,519
+446,799
| +2,842% | +$5.31M |
|
1219
Jefferies Financial Group
JEF
$12.9B
| $6.68M | ﹤0.01% |
108,494
+652
| +0.6% | +$37K |
|
1220
Korn Ferry
KFY
$4.28B
| $6.66M | ﹤0.01% |
88,450
+6,791
| +8% | +$477K |
|
1221
NETSCOUT
NTCT
$2.89B
| $6.65M | ﹤0.01% |
305,806
+258,005
| +540% | +$5.09M |
|
1222
WisdomTree
WT
$3.44B
| $6.5M | ﹤0.01% |
650,970
-9,099
| -1% | -$92.5K |
|
1223
Steven Madden
SHOO
$3.46B
| $6.5M | ﹤0.01% |
132,709
+4,909
| +4% | +$218K |
|
1224
ScottsMiracle-Gro
SMG
$3.62B
| $6.45M | ﹤0.01% |
74,386
-2,648,024
| -97% | -$186M |
|
1225
NeoGenomics
NEO
$2.11B
| $6.38M | ﹤0.01% |
432,540
-156,054
| -27% | -$2.44M |
|
Similar funds
T. Rowe Price Associates's Q3 2024 Portfolio in Review
As of Q3 2024, T. Rowe Price Associates held 3,059 positions worth $869B, up 3.9% from $836B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Trading was light in Q3 2024: portfolio turnover was 4.3%. T. Rowe Price Associates opened 82 new positions and exited 51, leaving the 3,059-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 32% of assets, down from 34% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q3 2024 buy was Lineage Inc: 4,699,854 shares worth $368M.
- T. Rowe Price Associates added most to Advanced Micro Devices in Q3 2024, an estimated $2.31B increase.
- T. Rowe Price Associates's biggest Q3 2024 reduction was NVIDIA, cutting an estimated $4.37B.
- T. Rowe Price Associates fully exited Morphic Holding, Inc. Common Stock in Q3 2024, selling an estimated $75.2M.
- T. Rowe Price Associates's ten largest holdings make up 34% of its $869B portfolio in Q3 2024.
- T. Rowe Price Associates opened 82 new positions and closed 51 in Q3 2024.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $869B.
Based on T. Rowe Price Associates's 13F filing for Q3 2024, filed 14 Nov 2024.